A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer

Cancer Investigation

Volumn 18, Issue 6, 2000, Pages 521-529

  Claire Dees, E ^a   O'Reilly, Seamus ^a   Goodman, Steven N ^a   Sartorius, Susan ^a   Levine, Marshall A ^a   Jones, Richard J ^a   Grochow, Louise B ^a   Donehower, Ross C ^a   Fetting, John H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ONDANSETRON; TAMOXIFEN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; COLONY FORMING UNIT GM; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; STEM CELL;

EID: 0343080998     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012191     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-5, 71-85, 1992.
2. Montamat SC, Cusack BJ, Vestal RE: Management of drug therapy in the elderly. N Engl J Med 321:303-309, 1989.
3. Balducci L, Parker M, Sexton W, et al: Pharmacology of antineo-plastic agents in the elderly patient. Semin Oncol 16:76-84, 1989.
4. Begg CB, Carbone PP: Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 52:1986-1992, 1983.
5. Begg CB, Cohen JL, Ellerton J: Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 3:369-374, 1980.
6. Bonadonna G, Zambetti M, Valagussa P, et al: Adjuvant CMF in node-negative breast cancer. Proc Am Soc Clin Oncol 5:74, 1986 (abstract 290).
7. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320:485-490, 1989.
8. Muss HB: Chemotherapy of breast cancer in the older patient. Semin Oncol 22(1 Suppl 1):14-16, 1995.
9. Gelman RS, Taylor SG: Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age-related trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984.
10. Kaijser GP, Beijnen JH: Oxazaphosphorines. In: A Clinician's Guide to Chemotherapy, Pharmacokinetics and Pharmacodynamics, edited by LB Grochow, MM Ames, Baltimore, Williams & Wilkins, 1998, pp. 229-258.
11. Robert J: Anthracyclines. In: A Clinician's Guide to Chemotherapy, Pharmacokinetics and Pharmacodynamics, edited by LB Grochow, MM Ames, Baltimore, Williams & Wilkins, 1998, pp. 93-174.
12. Robert J, Hoerni B: Age dependence of early-phase pharmacokinetics of doxorubicin. Cancer Res 43:4467-4469, 1983.
13. Levine MN, Guyatt GH, Gent M, et al: Quality of life in stage II breast cancer: an instrument for, clinical trials. J Clin Oncol 6: 1798-1810, 1988.
14. Chen TL, Passos-Coehlo JL, Noe DA, et al: Non-linearpharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous hone marrow transplantation. Cancer Res 55:810-816, 1995.
15. Mross K, Maessen P, vander Vijgh WJF, et al: Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517-526, 1988.
16. Metzler CM: Extended least squares for pharmacokinetic models. J Pharm Sci 76:565-571, 1987.
17. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978.
18. Jones RJ, Zuehlsdorf M, Rowley SD, et al: Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation. Blood 70:1490-1494, 1987.
19. Jones RJ, Sharkis SJ, Miller CB, et al: Bryostatin 1, a unique biologic response modifier: antileukemic activity in vitro. Blood 75:1319-1323, 1990.
20. Albain K, Green S, Osborne C, et al: Tamoxifen (T) versus cyclophosphamide, adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor( + ), node( + ) breast cancer: a Southwest Oncology Group phase III intergroup trial. Proc Am Soc Clin Oncol 16:128a, 1997 (abstract 450).
21. Mor V, Masterson-Allen S, Goldberg RJ, et al: Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc 33:585-589, 1985.
22. Fentiman IS, Tirelli U, Monfardini S, et al: Cancer in the elderly: why so badly treated? Lancet 335:1020-1022, 1990.
23. Silliman RA, Guadagnoli E, Weitberg AB, et al: Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol 44:M46-50, 1989.
24. Benson III AB, Pregler JP, Bean JA, et al: Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study J Clin Oncol 9:2067-2075, 1991.
25. Newcomb PA, Carbone PP: Cancer treatment and age: patient perspectives. J Natl Cancer Inst 85:1580-1584, 1993.
26. Lipschitz DA: Age-related declines in hematopoietic reserve capacity. Semin Oncol 22:3-5, 1995.
27. Balducci L, Extermann M: Cancer chemotherapy in the older patient. Cancer 80:1317-1322, 1997.
28. Rothstein G: Hematopoiesis in the aged: a model of hematopoietic dysregulation? Blood 9:2601-2604, 1993.
29. Borkowski JM, Duerr M, Donehower RC, et al: Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 33:493-496, 1994.
30. Baker SD, Grochow LB: Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 13:169-183, 1997.
31. Forbes JF: Long-term effects of adjuvant chemotherapy in breast cancer. Acta Oncol 31:243-250, 1992.
32. Shapiro CL, Recht A. Late effects of adjuvant therapy for breast cancer. Monogr Natl Cancer Inst 16:101-112, 1994.
33. Siu LL, Shepherd NM, Feld R, et al: Influence of age on the treatment of limited-stage small cell lung cancer. J Clin Oncol 14: 821-828, 1996.
34. Nou E: Full chemotherapy in elderly patients with small cell bronchial carcinoma. Acta Oncol 35:399-406, 1996.
35. Cascinu S, Del Ferro E, Catalano G: Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 19:371-374, 1996.
36. Fisher B, Anderson S, Wickerham L, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from NSABP B-22. J Clin Oncol 15:1858-1869, 1997.